IMS Health Belgium Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS? My loyalty to IMS Health lies in the opportunities I have been presented during all these years. Although I have…
A* Star Singapore’s proclaimed key strengths are: an educated and skilled workforce, a supportive government, great business and regulatory environment, and government-supported research institutes. What role has A* STAR played in building these capabilities? A decade ago the biomedical industry in Singapore was relatively modest and there was little research activities outside…
Australian Self Medication Industry (ASMI) As a general medical practitioner with a long experience in the pharmaceutical industry including public policy, advertising, marketing and regulatory issues and a post graduate training in traditional Chinese medicine, what made you decide to join ASMI as a Scientific Director in 2004 and Executive Director in July 2010? My…
Generic Medicines Industry Association (GMiA) In trying to be an effective association and positively influence the environment for your members, what have been the main achievements and milestones since you were appointed in 2008? We have been focusing on several strategic priorities over the past four years, firstly on creating a viable commercial environment for…
The Singapore Economic Development Board (EDB) Singapore is widely known as a key regional and global hub for companies to do business in. This reputation would not have been possible without the extensive work of the government. What have been the main driving forces that have allowed this agency to be at the forefront of effectively…
Beacons pharmaceuticals As one of the few surviving Singaporean manufactures, what has been the key to success? Our history spans more than 40 years and our success lies in our ability to manage costs. Furthermore, over the years we have managed to establish a strong brand and earned the reputation of quality…
Pronaos Dr. Sommermeyer, you’ve spent approximately two decades working for pharmaceutical companies throughout Europe. From a personal standpoint, why did you decide to leave the industry and found a consultancy? I started my career in research, and then moved to marketing and strategic planning. After ten years spent in headquarter functions,…
CMS Cameron McKenna Czech Republic Mr. Matějovský, let’s begin our discussion with a very simple question. The Czech Republic is quite a small country, and yet it seems to have one of the most complicated pharmaceutical regulatory frameworks in Europe–ensuring, for instance, that market access for drugs can take up to three years longer in…
MSD Belgium It truly seems that you have pharma in your genes, with a father who successfully developed a migraine drug in addition to your 4 years practicing medicine and now continuing an 18 year career with MSD. What distinguishes MSD as a pharmaceutical company in your opinion? At MSD, we are…
Servier Czech Republic You joined this affiliate in October of 2011, having spent the preceding three years as GM for Servier Slovakia. What are the principal differences you found between these two markets? The first difference is of course the size of the market—the Czech Republic has a market value of approximately 2Bn…
China Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China 2020’ goals as well as its unique business model and company culture. Fosun Pharma is an integrated pharmaceutical company with interests all along the value chain, from API to finished products, distribution, medical…
Hospira Hospira Mexico is not only the control centre for Central America and Caribbean operations, but it is the Latin American regional office. Why was such importance given to Mexico in this respect, and not for example, to Brazil? First of all, the Hospira model is a shared services model. It…
See our Cookie Privacy Policy Here